Posters

Toric Artiflex® phakic intraocular lens: refractive and functional results

Poster Details

First Author: T.Borges PORTUGAL

Co Author(s):    C. Vale   M. Seca   M. Lume   R. Salgado   M. Brochado        

Abstract Details

Purpose:

To evaluate the effectiveness, stability, safety and quality of vision of the foldable anterior chambre iris supported phakic intraocular lens (IOL) Toric Artiflex® (Ophtec®) for myopia and astigmatism correction.

Setting:

Centro Hospitalar do Porto, Portugal

Methods:

Retrospective analysis of 107 eyes of 74 patients, mean age 32,4±6,62 years, with myopia (-0.50 to -13:00 diopters (D)) and astigmatism (- 0.75 to - 5.25 D), that were implanted with the Toric Artiflex® Phakic IOL. Mean implanted spherical and cylindrical powers were -7,67±3,22D and -2,26±1,08D, respectively. Mean follow-up was 26,8 months (6 to 45 months). The authors evaluated the following parameters: uncorrected (UVA) and best corrected visual acuity (BCVA), intraocular pressure (IOP), morphometric evaluation (Orbscan II® and Pentacam HR®) endothelial cell density and morphology (specular microscopy with ICONAN®) and contrast sensitivity function (Metrovison® Vision Display).

Results:

Postoperative mean spherical equivalent was -0,07±0,23. BCVA improved from 0,84±0,19 to 0,94±0,11 with statistical significance. 59,8% had BCVA maintenance and 40,2% had improvement of BCVA (26,2% improved 1 line, 12,1% improved 2 lines and 1,9% improved 3 lines). The effectiveness index (postoperative UVA/preoperative BCVA) was 1,11. The safety index (postoperative BCVA/preoperative BCVA) was 1,12. Regarding IOP, endothelial cell count and contrast sensitivity, there was no statistically significant differences between preoperative and postoperative values. There was a case of traumatic subluxation of the IOL haptics that was surgically resolved and 11 cases (10,3%) of pigment precipitates on the surface of IOL.

Conclusions:

Toric Artiflex® Phakic IOL offers stable and predictable visual results thus providing a very high patient satisfaction. Any eye had loss of BCVA. With careful selection of patients, major safety complications, namely endothelial cell loss and cataract, were avoided.

Financial Disclosure:

NONE